Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results
(MedPage Today) -- Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results. While first-line pembrolizumab plus... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 1, 2024 Category: Hematology Source Type: news

Inadequate Knowledge: HPV and Oropharyngeal Carcinoma Inadequate Knowledge: HPV and Oropharyngeal Carcinoma
Dr Maurie Markman discusses a recent paper investigating knowledge about the relationship between HPV and oropharyngeal squamous cell carcinoma.Medscape Oncology (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 29, 2024 Category: Infectious Diseases Tags: Hematology-Oncology Commentary Source Type: news

Kimmtrak Tebentafusp Sales Increase By 64% In 2023
In the battle against melanoma, Kimmtrak has emerged as a groundbreaking treatment that offers an innovative approach of treatment with significant commercial potential. Although Kimmtrak is currently only approved for the treatment of uveal melanoma, clinical trials are being conducted to…#tebentafusp #immunocore (Source: Reuters: Health)
Source: Reuters: Health - February 29, 2024 Category: Consumer Health News Source Type: news

What ’s The Incidence Rate of a Second Primary Melanoma? What ’s The Incidence Rate of a Second Primary Melanoma?
The findings may have potential implications for more personalized surveillance of patients with melanoma, the authors said.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 29, 2024 Category: Internal Medicine Tags: Dermatology Source Type: news

Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs, according to a study published online Feb. 16 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2024 Category: Pharmaceuticals Source Type: news

European Approval for Lung and Skin Cancer Drugs European Approval for Lung and Skin Cancer Drugs
The European Medicines Agency granted marketing authorization for tislelizumab and retifanlimab for the treatment of non –small cell lung cancer and Merkel cell carcinoma, respectively.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 23, 2024 Category: Dermatology Tags: Hematology-Oncology Source Type: news

' Superclinic' Powers Through Skin Cancer Referrals'Superclinic' Powers Through Skin Cancer Referrals
One hospital ' s experience with this model shows the efficiency of using a dedicated team (including trainees) and offering same-day biopsies and surgery.Medscape News UK (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 23, 2024 Category: Dermatology Tags: Dermatology Source Type: news

FDA Approves 1st T-Cell Therapy For Melanoma
Authored by Amie Dahnke via The Epoch Times (emphasis ours), Melanoma cancer patients with solid tumors can turn to a new treatment thanks to the U.S. Food and Drug Administration’s (FDA) approval of a new class of immunotherapy. The new treatment may…#fda #amiedahnke #epochtimes #melanoma #amtagvi #samantharguild #aim #melanomafoundation #petermarks #hispanic (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news

News at a glance: Protecting a queen, cell therapy for solid tumors, and a UV telescope
CONSERVATION U.S. protects iconic marine snail The queen conch, a large marine snail known for its showy shell and delectable flesh, has been added to the U.S. government’s list of species threatened with extinction. Scientists at the National Oceanic and Atmospheric Administration (NOAA) said the species ( Strombus gigas , pictured), which is native to the Caribbean region and grows up to 35 centimeters long, needs protection because populations are sparse, scattered, and heavily overfished. NOAA’s listing decision, issued on 14 February, has no immediate impact but authorizes the age...
Source: ScienceNOW - February 22, 2024 Category: Science Source Type: news

FDA Approves New Cellular Therapy For Aggressive Skin Cancer
The FDA has granted accelerated approval to a new type of cellular therapy for use in people who have skin cancer that has spread to other parts of the body. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 21, 2024 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business pharma & standard Source Type: news

Iovance stock soars on FDA approval of its melanoma gene therapy
Iovance has its gene therapy manufacturing plant at the Philadelphia Navy Yard. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 20, 2024 Category: Biotechnology Authors: John George Source Type: news

Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first cellular therapy approved to treat this form of solid tumor cancer. " The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 20, 2024 Category: Pharmaceuticals Source Type: news

FDA Grants Accelerated Approval for Amtagvi (lifileucel) for the Treatment of Advanced Melanoma
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2024 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Treatment for Advanced Melanoma, Amtagvi
MONDAY, Feb. 19, 2024 -- The U.S. Food and Drug Administration has approved a novel treatment for advanced melanoma, the most deadly form of skin cancer. Amtagvi, made by Iovance Biotherapeutics Inc., becomes the first cellular therapy approved to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 19, 2024 Category: General Medicine Source Type: news

Miami Cancer Institute to host second Precision Oncology Symposium to advance cancer treatment
Miami Cancer Institute, part of Baptist Health South Florida, will host its second annual Precision Oncology Symposium from April 19-20, according to the symposium organizers. This one-and-a-half-day symposium, to be held in Miami, has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors — including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas, and brain… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 19, 2024 Category: Biotechnology Authors: Baptist Health Source Type: news